Compare Snap On Incorporated (SNA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs Travere Therapeutics Inc. Common Stock — how do they compare? Snap On Incorporated trades at $362.71 (market cap $18.81B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Snap On Incorporated is far larger — about 3.9× Travere Therapeutics Inc. Common Stock's market cap, and Snap On Incorporated pays a 2.68% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Snap On Incorporated for 38 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SNA | TVTX | |
|---|---|---|
Market Cap | $18.81B | $4.88B |
Volume | 239,235 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $419.31 | $67.52 |
52-Week Low | $328.69 | $26.79 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $18.45B | $5.01B |
Dividend Yield | 2.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-On Incorporated (SNA) trades at $363.67, up 0.46% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 19.6% and ROE of 17.58%, while Q2 2026 earnings beat estimates. Recent news highlights gross margin expansion and institutional trading activity.
The outlook is supported by analyst consensus with a $449 price target and 66.7% buy ratings, but risks include valuation premiums and mixed segment trends. Earnings growth and RCI initiatives remain key catalysts, though integration costs and softer OEM demand pose near-term challenges.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
